Biomarkers in the Breathless: A New Study Validates Diagnostic Accuracy in a High-Mortality Setting
A landmark prospective study from Malawi provides critical data on the diagnostic accuracy of key laboratory biomarkers for patients hospitalized with acute breathlessness. The research, published in *Thorax*, evaluated the performance of natriuretic peptides for heart failure and procalcitonin (PCT) and C-reactive protein (CRP) for pneumonia in a real-world, low-resource setting. The findings revealed that brain natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) showed excellent diagnostic accuracy for heart failure, with area under the curve (AUC) values of 0.89 and 0.88, respectively. For pneumonia, CRP (AUC 0.77) outperformed PCT (AUC 0.69). The study underscores the high mortality associated with breathlessness in this population and highlights the complex, multifactorial nature of these admissions, with most patients suffering from multiple co-existing conditions like heart failure, anemia, and tuberculosis.
Study Significance: For professionals in laboratory medicine and clinical chemistry, this study validates the robust performance of established cardiac biomarkers like BNP and NT-proBNP in a challenging, high-acuity population, reinforcing their role in diagnostic algorithms for heart failure. The comparative data on CRP and PCT for pneumonia informs test selection and interpretation in settings where antimicrobial stewardship is crucial. The research directly speaks to the need for integrated diagnostic pathways and underscores the importance of clinical correlation, as most cases involved multiple diagnoses, moving beyond single-disease testing models.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
